Evidence map›Paper›PMID 41923388›Full record

ArticleDrug development research2026

A LAT1-Compatible, Leadlike Tyrosine-Naphthoquinone Conjugate With Anticancer Activity.

Austin Seymour, Christian Peterson, Raymond Osafo, Abdullahi A Ashimi, Dylan Williams, Laura Echezabal, Chelsea Carrier, Alysa Clarke, Clifford W Padgett, Mark Vincent C Dela Cerna and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Austin SeymourBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Christian PetersonBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Raymond OsafoBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Abdullahi A AshimiBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Dylan WilliamsBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Laura EchezabalBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Chelsea CarrierBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Alysa ClarkeBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
Clifford W PadgettBiochemistry, Chemistry, and Physics Department, Science Center, Georgia Southern University, Savannah, Georgia, USA.
Mark Vincent C Dela CernaBiochemistry, Chemistry, and Physics Department, Science Center, Georgia Southern University, Savannah, Georgia, USA.
Zheni UticMathematical Sciences Department, University Hall, Georgia Southern University, Savannah, Georgia, USA.
Divine WandukuStatistical Consulting Unit (SCU), Department of Mathematical Sciences, Statesboro, Georgia, USA.
Nathaniel ShankBiochemistry, Chemistry, and Physics Department, Science Center, Georgia Southern University, Savannah, Georgia, USA.
Karelle S AikenBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.ORCID https://orcid.org/0000-0002-2131-5373
Jannet KocerhaBiochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.

Funding

The Design and Study of Anticancer Therapeutics Inspired by Natural Substrates of LAT1R15CA277652 · NCI · GEORGIA SOUTHERN UNIVERSITY · PI AIKEN, KARELLE, KOCERHA, REBECCA JANNET · 2023 to 2023
$425k
NCI NIH HHS R15 CA277652NIH HHS 1R15CA277652-01
6 · The paper itself

Abstract

A L-type amino acid transporter 1 (LAT1)-compatible, anticancer-active tyrosine-naphthoquinone (NQ) conjugate was successfully developed. The conjugate was designed to exploit LAT1 overexpression in cancers with the goal of achieving selective cytotoxicity for cancerous over noncancerous cells. The tyrosine-NQ molecule was subjected to cell viability, imaging, docking and in silico pharmacological studies along with structure-activity relationship (SAR) assessment. Cell viability investigations included IC

Indexed as

Antineoplastic AgentsLarge Neutral Amino Acid-Transporter 1NaphthoquinonesTyrosineCell Line, TumorCell SurvivalHEK293 CellsHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsLarge Neutral Amino Acid-Transporter 1NaphthoquinonesSLC7A5 protein, humanTyrosineleadlikeL‐type amino acid transporter 1 (LAT1)tyrosine‐naphthoquinone conjugate

Identifiers

PMID41923388
PMCPMC13044391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.